| Identification | Back Directory | [Name]
INDEX NAME NOT YET ASSIGNED | [CAS]
2413035-41-1 | [Synonyms]
(2S，4R)-1-[(2S)-2-{2-[4-(4-{3-[2,6-difluoro-3-(propane-1-sulfonamido)Benzoyl]-1Hpyrrolo[2,3-b]pyridin-5-yl}phenyl)piperazin-1-yl]acetamido}-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazole-5-yl)pyrrolidin-2-carboxylic acid amide | [Molecular Formula]
C51H57F2N9O7S2 | [MOL File]
2413035-41-1.mol | [Molecular Weight]
1010.19 |
| Chemical Properties | Back Directory | [density ]
1.368±0.06 g/cm3(Predicted) | [solubility ]
DMSO:101.02(Max Conc. mg/mL);100.0(Max Conc. mM) | [form ]
Solid | [pka]
6.29±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
SJF-0628 (compound 512) is a PROTAC RAF degrader. SJF-0628 induces targeted degradation of BRAF mutants (DC50: 5.4 nM, 4.64 nM, 15.5 nM, 2.11 nM, 63.9 nM for BRAF V600E, V600K, G464V, G469A, K601E respectively). SJF-0628 has anti-tumor activity. SJF-0628 can be used for research of disorders that result from aggregation or accumulation of RAF, or the constitutive activation of RAF[1]. | [storage]
Store at -20°C | [References]
[1] Andrew P. Crew, et al. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides. Patent. US 20200129627 A1.
[2] Chapdelaine AG, et al. The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells. Cancers (Basel). 2023 Dec 12;15(24):5805. DOI:10.3390/cancers15245805 |
|
|